Asmodium falciparum identification and tracking. Malar J 2008, 7:223. Trager W, Jensen JB: Human malaria parasites in continuous culture. Science 1976, 193:67375. Plouffe D, Brinker A, McNamara C, Henson K, Kato N, Kuhen K, Nagle A, Adrian F, Matzen JT, Anderson P, Nam TG, Gray NS, Chatterjee A, Janes J, Yan SF, Trager R, Caldwell JS, Schultz PG, Zhou Y, Winzeler EA: In silico activity profiling reveals the mechanism of action of antimalarials found in a high-throughput screen. Proc Natl Acad Sci U S A 2008, 105:9059064. Zhang JH, Chung TD, Oldenburg KR: A basic statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999, 4:673.Van Tyne et al. Malaria Journal 2013, 12:441 http://www.malariajournal/content/12/1/Page ten of25. Mita T, Kaneko A, Lum JK, Bwijo B, Takechi M, Zungu IL, Tsukahara T, Tanabe K, Kobayakawa T, Bjorkman A: Recovery of chloroquine sensitivity and low prevalence from the Plasmodium falciparum chloroquine resistance transporter gene mutation K76T following the discontinuance of chloroquine use in Malawi. Am J Trop Med Hyg 2003, 68:41315. 26. Sa JM, Twu O, Hayton K, Reyes S, Fay MP, Ringwald P, Wellems TE: Geographic patterns of Plasmodium falciparum drug resistance distinguished by differential responses to amodiaquine and chloroquine. Proc Natl Acad Sci U S A 2009, 106:188838889. 27. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Cost RN, Ringwald P: A systematic critique and meta-analysis of evidence for correlation involving molecular markers of parasite resistance and therapy outcome in falciparum malaria. Malar J 2009, 8:89. 28. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM: Association involving mutations in Plasmodium falciparum chloroquine resistance transporter and P.S1p receptor agonist 1 falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P.Emodepside falciparum malaria-infected kids in Nigeria. Am J Trop Med Hyg 2006, 75:15561. 29. Pascual A, Parola P, Benoit-Vical F, Simon F, Malvy D, Picot S, Delaunay P, Basset D, Maubon D, Faugere B, Menard G, Bourgeois N, Oeuvray C, Didillon E, Rogier C, Pradines B: Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with standard ACT drugs against isolates of Plasmodium falciparum. Malar J 2012, 11:45. 30. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G: Selection of Plasmodium falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an location of Uganda exactly where malaria is very endemic. Antimicrob Agents Chemother 2006, 50:1893895. 31. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, Gadalla A, Mansour F, Warhurst D, El-Sayed BB, Sutherland CJ: Improved pfmdr1 copy quantity and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria individuals treated with artemether-lumefantrine.PMID:24013184 Antimicrob Agents Chemother 2011, 55:5408411. 32. Wurtz N, Fall B, Pascual A, Diawara S, Sow K, Baret E, Diatta B, Fall KB, Mbaye PS, Fall F, Dieme Y, Rogier C, Bercion R, Briolant S, Wade B, Pradines B: Prevalence of molecular markers of Plasmodium falciparum drug resistance in Dakar, Senegal. Malar J 2012, 11:197. 33. Fall B, Pascual A, Sarr FD, Wurtz N, Richard V, Baret E, Dieme Y, Briolant S, Bercion R, Wade B, Tall A, Pradines B: Plasmodium falciparum susceptibility to anti-malarial drugs in Dakar, Senegal, in 2010: an ex vivo and drug resistance molecular markers study. Malar J two.
Related Posts
A present from John Lee, Smith Kline French) for 20 min before adherence.
A present from John Lee, Smith Kline French) for 20 min before adherence. Genistein or SK F 86002 was dissolved in dimethyl sulfoxide (DMSO) and added towards the medium to a final concentration of 0.1 of DMSO. DMSO (0.1)does not interfere with mRNA stability or the mobility shift activity (data not shown). RNA isolation and […]
Substrate initially present remained intact soon after a 15-min incubation employing a
Substrate initially present remained intact right after a 15-min incubation working with a 7-fold molar excess of DHFR-GAr30-GFP-ssrA more than ClpXP complicated (Fig. 1B, top rated left). The reaction created a trace volume of a fragment using the approximate size of DHFR, an intermediate remnant resulting from ClpXP degradative processing that destroys GFP-ssrA. The volume […]
Uring 2006016 (Table 3). The results indicate that the Icosabutate custom synthesis built-up development in
Uring 2006016 (Table 3). The results indicate that the Icosabutate custom synthesis built-up development in KMA was dispersed, and became more dispersed with time. The Hn of mixed built-up has been much ML-SA1 Agonist greater than that of mixed built-up cover more than the years. It indicates that urban growth via mixed built-up spread was […]